Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Publications
2 shownTwo Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
These two phase 3 studies show the efficacy of canakinumab in systemic JIA with active systemic features. (Funded by Novartis Pharma; ClinicalTrials.gov numbers, NCT00889863 and...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 1,524
- Institution
- Bicêtre Hospital
External Links
Identifiers
- ORCID
- 0000-0001-8939-5763
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.